Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States

Plotkin, Stanley А.

doi:10.1001/jama.225.6.585

Cited by 71 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early experience in the United States with the HPV-77 DK12 strain vaccine revealed such an increase of postvaccination rubella-like symptoms, including arthralgia and frank arthritis, resulting in its voluntary withdrawal from the market in 1970. The RA 27/3 strain vaccine replaced all HPV-77 vaccines in the United States market in 1979 because it was more immunogenic and caused relatively fewer adverse side reactions [13].…”

Section: Side Effects and Adverse Reactions To Rubella Vaccinationmentioning

confidence: 99%

Rubella in the United States: toward a strategy for disease control and elimination

Herrmann

1991

Epidemiol. Infect.

View full text Add to dashboard Cite

More than 25 years have passed since the last rubella epidemic in the United States. The rubella pandemic of 1964–5 demonstrated clearly the extraordinary teratogenic potential of the rubella virus. In the United States alone, it is estimated that more than 12500000 cases of rubella occurred during the winter and spring of 1964–5. Congenital rubella infection occurred in an estimated 30000 pregnancies, 10000 resulting in fetal death or therapeutic abortion and 20000 resulting in infants born with congenital rubella syndrome (CRS) [1]. In contrast, during 1988, only 225 cases of rubella were reported to the Centers for Disease Control (CDC) in Atlanta, the lowest annual total since rubella became a nationally notifiable disease in 1966 [2]. However, in 1989, this downward trend of reported cases was interrupted, with the number of reported rubella cases in the United States increasing nearly twofold, and in 1990, the total increased another threefold (to more than 1000 cases) [3]. Although the 1990 reports represent the highest total since 1982, the overall incidence of rubella in the United States has still declined by more than 98% since 1969, the year rubella vaccine was licensed (Fig. 1).

show abstract

Section: Side Effects and Adverse Reactions To Rubella Vaccinationmentioning

confidence: 99%

Rubella in the United States: toward a strategy for disease control and elimination

Herrmann

1991

Epidemiol. Infect.

View full text Add to dashboard Cite

show abstract

“…And of course the vaccine accomplishments of Wistar researchers were known to all-Stanley Plotkin, Thad Wiktor, and Koprowski himself-had contributed enormously to public health with the inventions of the rubella (1) and the cell-based rabies vaccines. (2) The Wistar Rabies Unit run by Thad Wiktor was recognized internationally.…”

mentioning

confidence: 99%

Hilary Koprowski and the Viral Immunity Hub at the 1980s Wistar Institute: A T Cell Epitope Perspective

Hackett

2014

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

View full text Add to dashboard Cite

“…Diversas pesquisas feitas no sentido de avaliar a eficiência das vacinas atualmente disponíveis 4,18,21,30 comparam os níveis de anticorpos inibidores da hemaglutinação e anticorpos neutralizantes conseguidos com o processo vacinal, com os que se desenvolvem na infecção natural. Raramente fazem referência aos anticorpos fixadores do complemento, considerando vários autores que estes não se formam na infecção vacinal 11,13,24,43 .…”

unclassified

“…Raramente fazem referência aos anticorpos fixadores do complemento, considerando vários autores que estes não se formam na infecção vacinal 11,13,24,43 . Tal conceito não tem mais razão para aceitar-se, uma vez que, respeitando determinadas técnicas, é possível detectar a presença de anticorpos fixadores do complemento como resposta à vacinação contra a rubéola 19,30,36 .A finalidade da presente pesquisa é avaliar a eficiência da vacina Wistar RA 27/3, …”

unclassified

Resposta sorológica de adultos à vacinação contra a rubéola

1977

View full text Add to dashboard Cite

INTRODUÇÃOA imunização contra a rubéola é feita com vacinas vivas atenuadas preparadas com diversas cepas de vírus, sendo, de um modo geral, muito satisfatórios os resultados obtidos, em todos os aspectos sob que possam querer analisar-se. Diversas pesquisas feitas no sentido de avaliar a eficiência das vacinas atualmente disponíveis 4,18,21,30 comparam os níveis de anticorpos inibidores da hemaglutinação e anticorpos neutralizantes conseguidos com o processo vacinal, com os que se desenvolvem na infecção natural. Raramente fazem referência aos anticorpos fixadores do complemento, considerando vários autores que estes não se formam na infecção vacinal 11,13,24,43 . Tal conceito não tem mais razão para aceitar-se, uma vez que, respeitando determinadas técnicas, é possível detectar a presença de anticorpos fixadores do complemento como resposta à vacinação contra a rubéola 19,30,36 .A finalidade da presente pesquisa é avaliar a eficiência da vacina Wistar RA 27/3,

show abstract

Immunologic properties of RA27-3 rubella virus vaccine. A comparison with strains presently licensed in the United States

Cited by 71 publications

References 17 publications

Rubella in the United States: toward a strategy for disease control and elimination

Rubella in the United States: toward a strategy for disease control and elimination

Hilary Koprowski and the Viral Immunity Hub at the 1980s Wistar Institute: A T Cell Epitope Perspective

Resposta sorológica de adultos à vacinação contra a rubéola

Contact Info

Product

Resources

About